Ramucirumab, a humanized recombinant IgG1 monoclonal antibody, selectively binds to VEGFR-2, preventing activation of the VEGF pathway (Fig. 4) [36], and it showed anti-tumor activity in advanced HCC in a phase II trial [37]. Here, VEGFA is linked to neoplasm.